Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01750957 · ClinicalTrials.gov registry record · Phase 2
A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome
A Phase 2 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT01750957 is a Phase 2 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 47 participants.
The verdict
NCT01750957, a Phase 2 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
This randomized, double-blind, placebo-controlled, parallel-arm study will evaluate the safety and exploratory efficacy and pharmacokinetics of RO4917523 in pediatric patients with fragile X syndrome. Patients will be randomized to receive one of 2 dose levels of RO4917523 or placebo orally daily for 12 weeks.
Interventions
- DRUG Placebo
- DRUG RO4917523
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01750957
The ClinicalTrials.gov registry entry for NCT01750957 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01750957 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01750957 about?
NCT01750957 is a clinical study titled "A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome". This randomized, double-blind, placebo-controlled, parallel-arm study will evaluate the safety and exploratory efficacy and pharmacokinetics of RO4917523 in pediatric patients with fragile X syndrome. Patients will be randomized to receive one of 2 dose levels of RO4917523 or placebo orally daily fo...
What is the current status of trial NCT01750957?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2013-02. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01750957?
The interventions under investigation include: Placebo (DRUG), RO4917523 (DRUG).
Who is sponsoring clinical trial NCT01750957?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.